



# The London Gazette

Published by Authority

Registered as a Newspaper at the Post Office

FRIDAY, 27<sup>TH</sup> JUNE 1997

## State Intelligence

PRIVY COUNCIL OFFICE

Notice is hereby given that a Petition has been presented to Her Majesty in Council by the Worshipful Company of Basketmakers praying for the grant of a Supplemental Charter.

Her Majesty having referred the said Petition to a Committee of the Lords of the Privy Council, all Petitions for or against such grant should be delivered at the Privy Council Office, 68 Whitehall, London SW1A 2AT, on or before the 16th July next. (4 SI)

TREASURY SOLICITOR

MURAD CONSTRUCTIONAL LIMITED

*Notice of Disclaimer under section 656 of the Companies Act 1985*

In pursuance of the powers granted by section 656 of the Companies Act 1985, the Solicitor for the Affairs of Her Majesty's Treasury in whom the property and rights of Murad Constructional Limited (No. 00510971) (hereinafter called "the Company") vested pursuant to section 654 of the Companies Act 1985 on the dissolution of the Company hereby disclaims the Crown's interest (if any) in 70-76 Limes Avenue, Aylesbury, Buckinghamshire, the vesting of the property having come to his notice on 26th June 1996.

Assistant Treasury Solicitor

18th June 1997.

(3 SI)

## DEPARTMENT OF HEALTH

MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ.  
Telephone 0171-273 0422 or 0425

### Product Licences Granted

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
00010/0220	Bayer PLC	Ciproxin IV Flexibag	Ciprofloxacin 200-000 mg	For the treatment of the following infections caused by sensitive bacteria: Severe systemic infections: e.g. septicaemia, bacteraemia, peritonitis, infections in immuno-suppressed patients with haematological or solid tumours and in patients in intensive care units with specific problems such as infected burns. Respiratory tract infections e.g. lobar and bronchopneumonia, acute and chronic bronchitis, acute exacerbation of cystic fibrosis, bronchiectasis, empyema. Ciprofloxacin is not recommended as first-line therapy for the treatment of pneumococcal pneumonia. Ciprofloxacin may be used for treating Gram-negative pneumonia. Ear, nose and throat infections; e.g. mastoiditis, otitis media and sinusitis, especially if due to Gram-negative bacteria (including <i>Pseudomonas</i> spp.).	13th March 1997